CA3128152A1 - Sulcardine salts - Google Patents

Sulcardine salts Download PDF

Info

Publication number
CA3128152A1
CA3128152A1 CA3128152A CA3128152A CA3128152A1 CA 3128152 A1 CA3128152 A1 CA 3128152A1 CA 3128152 A CA3128152 A CA 3128152A CA 3128152 A CA3128152 A CA 3128152A CA 3128152 A1 CA3128152 A1 CA 3128152A1
Authority
CA
Canada
Prior art keywords
sulcardine
solid form
salt
peaks
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128152A
Other languages
English (en)
French (fr)
Inventor
Suzanne J. Romano
Hayley Ann REECE
Joseph Edward Gordon Benson
Sarah COLLINS
Gary T. Elliott
Mireille GILLINGS
Robert Goodenow
Curtis TYREE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Huya Bioscience International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience International LLC filed Critical Huya Bioscience International LLC
Publication of CA3128152A1 publication Critical patent/CA3128152A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
CA3128152A 2019-01-29 2020-01-28 Sulcardine salts Pending CA3128152A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US62/798,467 2019-01-29
US202062959687P 2020-01-10 2020-01-10
US62/959,687 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Publications (1)

Publication Number Publication Date
CA3128152A1 true CA3128152A1 (en) 2020-08-06

Family

ID=69724142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128152A Pending CA3128152A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Country Status (16)

Country Link
US (3) US11426382B2 (https=)
EP (1) EP3917921A1 (https=)
JP (3) JP2022518906A (https=)
KR (2) KR102405199B1 (https=)
CN (2) CN115385871A (https=)
AU (1) AU2020216925B2 (https=)
BR (1) BR112021014640A8 (https=)
CA (1) CA3128152A1 (https=)
CL (1) CL2021001968A1 (https=)
CO (1) CO2021011042A2 (https=)
IL (1) IL285184B2 (https=)
MX (2) MX2021009033A (https=)
PH (1) PH12021551818A1 (https=)
SG (1) SG11202108160YA (https=)
WO (1) WO2020159959A1 (https=)
ZA (2) ZA202105344B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
CA3182015A1 (en) 2020-06-12 2021-12-16 Gary Elliott Sulcardine administration for treatment of acute atrial fibrillation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CN102665714A (zh) 2009-11-17 2012-09-12 沪亚生物国际有限责任公司 心房纤颤的治疗
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
CA3023278C (en) 2016-05-05 2019-04-30 Triastek, Inc. Controlled release dosage form
KR20190107712A (ko) 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
CA3054403A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐

Also Published As

Publication number Publication date
BR112021014640A8 (pt) 2022-12-20
US20200316024A1 (en) 2020-10-08
PH12021551818A1 (en) 2022-03-28
KR102405199B1 (ko) 2022-06-02
AU2020216925B2 (en) 2022-09-15
ZA202105344B (en) 2023-01-25
KR20220079688A (ko) 2022-06-13
KR102697726B1 (ko) 2024-08-21
AU2020216925A1 (en) 2021-09-02
IL285184A (en) 2021-09-30
BR112021014640A2 (pt) 2021-09-21
US20250144072A9 (en) 2025-05-08
US11426382B2 (en) 2022-08-30
CL2021001968A1 (es) 2022-01-28
ZA202107474B (en) 2022-06-29
JP2024039020A (ja) 2024-03-21
IL285184B2 (en) 2023-12-01
IL285184B1 (en) 2023-08-01
EP3917921A1 (en) 2021-12-08
US20210038568A1 (en) 2021-02-11
US11020374B2 (en) 2021-06-01
KR20210130157A (ko) 2021-10-29
JP2022518906A (ja) 2022-03-17
US20220356319A1 (en) 2022-11-10
CO2021011042A2 (es) 2022-01-17
MX2023014776A (es) 2024-01-15
JP2025165933A (ja) 2025-11-05
CN115385871A (zh) 2022-11-25
WO2020159959A1 (en) 2020-08-06
CN112638903B (zh) 2022-08-26
CN112638903A (zh) 2021-04-09
MX2021009033A (es) 2021-10-13
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
US20220356319A1 (en) Sulcardine salts
AU2019202144A1 (en) Solid forms of {(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino}acetic acid, compositions, and uses thereof
BR112020022738A2 (pt) formas cristalinas de um inibidor tlr7/tlr8
JP2016513678A (ja) 複素環式化合物及びそれらの使用
JP2023550428A (ja) インテグリン阻害剤およびその使用
PT779283E (pt) Monohidratos de derivados do acido aminobenzenosulfonico e metodo para a sua preparacao
EA026232B1 (ru) Кристаллическая форма а фосфатной соли 4-(r)-(6,7-дигидро-5h-пиррол[1,2-с]имидазол-5-ил)-3-фторбензонитрила, способ её получения и применение
US20180111903A1 (en) Crystalline Forms of Cabozantinib Phosphate And Cabozantinib Hydrochloride
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
US8361971B2 (en) Tablet formulation of ezatiostat
HK40079384A (en) Sulcardine salts
HK40049638B (en) Sulcardine salts
HK40049638A (en) Sulcardine salts
EA043571B1 (ru) Соли сулькардина
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
RU2663617C1 (ru) Новая кристаллическая форма метансульфонат 5-хлор-n-({ (5s)-2-оксо-3-[4-(5,6-дигидро-4h-[1,2,4]триазин-1-ил)фенил]-1,3-оксазолидин-5-ил} метил)тиофен-2-карбоксамида и содержащая его фармацевтическая композиция
BR112015008931B1 (pt) Forma cristalina de (3s,3s) 4,4-disulfanodiilbis(ácido 3-aminobutano 1-sulfônico) de absd; processo para a preparação de uma forma cristalina de absd e l-lisina; e composição farmacêutica
US10611772B2 (en) Crystalline form of Ribociclib succinate
JP2025530060A (ja) 高尿酸血症または痛風を治療若しくは予防するための化合物の固体結晶形
CA3288303A1 (en) Pentamidine analogue polymorphs, formulations, and methods thereof
EA042489B1 (ru) Фармацевтическая композиция, включающая сакубитрил и валсартан
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241011

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250531

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250531

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251223